1. Introduction {#sec1}
===============

The prognosis of patients who receive appropriate treatment for thyroid carcinoma is usually favourable, especially for differentiated thyroid carcinoma (DTC). However, although most patients have a long-term survival rate, 5% to 20% of patients will develop recurrence during the followup, primarily in the cervical lymph nodes (LNs) \[[@B1], [@B2]\]. These LNs metastases may be detected clinically, but now are most often discovered on ultrasonography (US) \[[@B3]\]. It is of great importance to differentiate accurately LN metastases from benign reactive lymph nodes in order to avoid unnecessary treatment, but also to treat metastatic patients without delay. As consequence, diagnostic procedures must offer good sensitivity, but also high negative predictive value. US criteria distinguishing benign from metastatic or suspicious LNs have been described but they lack accuracy \[[@B4]\]. US-guided fine needle cytology (FNAC) proved to be a reliable method in examining the neck in patients who were previously treated for thyroid cancer \[[@B5], [@B6]\]. However, sensitivity of FNAC is far from excellent, varying from 75% to 85%, and altered by high rate of nondiagnostic or false-negative samples. To improve the diagnostic yield of FNAC, several authors have proposed measurement of Tg in aspirates (FNAC-Tg), particularly in the cases involving small, partially cystic, lymph nodes \[[@B7]--[@B12]\]. On the basis of prior studies, an increased Tg level in the needle washout has been shown to directly reflect the status of metastatic lymph nodes in patients affected by differentiated thyroid carcinoma. However, controversies still persist concerning some issues. First, there are few studies to validate the benefit of FNAC-Tg over FNAC alone, and, second, cut-off values ranging from 0.9 to 39 ng/mL have been suggested for FNAC-Tg, depending on the method used for the measurement \[[@B7], [@B13]--[@B15]\]. As consequence, the exact place for FNAC-Tg in the management of DTC patients is still debated. This study was then undertaken to (1) determine a diagnostic cut-off value for washout Tg in patients treated by total thyroidectomy for detecting recurrences, and (2) to compare the performance of the Tg cut-off value to US-guided FNAC for detecting DTC recurrences.

2. Materials and Methods {#sec2}
========================

Our institutional review board approved our research study, and all subjects gave written informed consent.

2.1. Patients {#sec2.1}
-------------

Between January 2006 and February 2009 a total of 126 consecutive US-guided FNACs were performed on enlarged LNs. The samples were obtained from 108 patients (19 males, 89 females; age 42.7 ± 18.2 years; 91 patients with 1, 94 with 2, and 5 with 3 lesions, resp.). All patients had histologically confirmed primary DTC (papillary, *n* = 99, including two tall-cell variants; follicular, *n* = 9, including 2 Hürtle cells carcinomas). The primitive carcinoma was classified pT1 in 34 cases, pT2 in 43 cases, pT3 in 24 cases, and pT4 in 7 cases. Forty-five patients (42%) had LN metastases at diagnosis. All patients underwent (near) total thyroidectomy and subsequent radioiodine ablation (administered activity from 1.85 to 3.70 GBq). The US criteria for possible malignant infiltration of lymph nodes were rounded contour, irregular internal echogenicity, punctate calcifications, fluids components, and abnormal colour Doppler pattern. Patients with positive cytology and/or FNAC-Tg measurement (*n* = 86, 96 lesions) underwent surgery and, if necessary, further radioiodine treatments. The diagnosis was confirmed in all cases by surgical pathology examination. Patients with negative FNAC-Tg measurement and cytology (*n* = 22, 30 lesions) underwent further follow up by serial clinical examinations, serum Tg measurements, neck US, and, whenever necessary, additional imaging procedures (i.e., radioiodine scan, ^18^FDG-PET/CT). No DTC recurrence was detected among these patients (follow up: mean 36 months, range 15--42 months).

2.2. US-Guided FNAC Procedure {#sec2.2}
-----------------------------

All US-guided FNAC procedures were performed on supine patients with the neck hyperextended under continuous real-time US guidance with a high-resolution transducer (ACUSON ×150, Siemens, Erlangen, Germany). Each lesion was aspirated at least twice by a 21 G needle. The needle was inserted obliquely within the transducer plane of view, and moved back and forth through the nodule to compensate for patient movement and needle deflection. Gradual aspiration was applied by a 20 mL syringe connected to Cameco\'s device. Contents of needles were expelled onto glass slides and smeared with a second slide to spread fluid across the surface. Slides were fixed in 95% ethanol, papanicolaou stained to identify cellular details, and read by our cytopathologist. Following collection of cytology samples the needles were washed by 1 mL of normal saline in a plain serum tube (Vacutainer Systems, Plymouth, UK) and the washout directly sent to the laboratory \[[@B16]\]. Cytological examinations were performed by experienced cytopathologists and expressed as (1) positive: presence of epithelial cells with atypical cytological characteristics, or with cytological features of papillary carcinoma; (2) negative: reactive lymphadenitis and absence of malignant cells; (3) inadequate or nondiagnostic: absence of cells or presence of blood cells.

2.3. Tg Measurement {#sec2.3}
-------------------

Thyroglobulin was measured in fine-needle washouts using an immunoradiometric assay (IRMA) based on coated tubes with monoclonal antibodies directed against distinct epitopes of the molecule of Tg (DYNO test Tg-plus, BRAHMS Diagnostic GmbH, Berlin, Germany). With this measurement, analytic sensitivity, defined as the detectable minimum concentration different from zero (mean value + 2 standard deviation), and functional sensitivity, defined as the lowest value that was measured with the precision of a maximum 20% interassay variance, were 0.08 ng/mL and 0.2 ng/mL, respectively. We did not measure Tg antibodies (FNAC-TgAb) because the clinical performance of FNAC-Tg is unaffected by serum TgAb \[[@B17]\].

2.4. Data Analysis {#sec2.4}
------------------

Diagnostic performance (i.e., sensitivity, specificity, positive predictive value, negative predictive value, and accuracy) of FNAC and FNAC-Tg was evaluated by comparing the results of the two procedures to the status of the patients defined as follows: malignant lymph node from thyroid cancer was proved by histological examination of surgically resected LNs; benign lymph node was proved by negative histological examination of surgically respected LNs, or if disappearance or absence of evolution on imaging modalities was demonstrated at 12 months or more follow up.

The Chi-square (*χ*^2^) test, performed with SAS version 9.1 for Windows (SAS Institute, Cary, NC, US) was employed to compare the diagnostic rate of FNAC and FNAC-Tg. The FNAC-Tg receiver operating characteristic curve was developed using MedCalc 6.1 software (MedCalc Software, Mariakerke, Belgium). The cut-off values which maximise the sum of sensitivity plus specificity were determined as the points in the upper left hand corner. A *P* value \<.05 was considered to indicate statistical significance.

3. Results {#sec3}
==========

Patients characteristics and cytological, pathological, and biochemical data are displayed in [Table 1](#tab1){ref-type="table"}. Of the 126 lymph node lesions assessed for postoperative recurrences by US-guided FNAC and FNAC-Tg, 86 (68%) lesions were finally diagnosed as malignant and the remaining 40 (32%) lesions were diagnosed as benign LNs, respectively. The final diagnosis of the 86 malignant and 8 benign LN was established by surgical pathology; the remaining 32 benign lesions were diagnosed based on imaging follow up after at least 1 year. The time from thyroid ablation to US-FNAC was 19.5 ± 14.31 and 19.4 ± 13.76 months in patients with benign and malignant lesions, respectively (*P* not significant). Serum Tg levels were higher in patients with malignant lesions (median 4.20 ng/mL, range \<0.2--27.10 ng/mL) than those with benign lesions (median  .80 ng/mL, range \<0.2--2.70 ng/mL; *P* \< .0001). Serum TgAb were positive in 11 of 40 patients with benign lesions and 7 of 67 patients with malignant lesions (*P* \< .001). The rate of FNAC samples adequate for cytological examination was 77% (97 samples) in contrast FNAC-Tg available in 100% of aspirates (*P* \<  .01). As shown in [Table 2](#tab2){ref-type="table"} cytological examination correctly identified 61 malignant LNs, was negative in 4, and inadequate in 21. For benign LNs, FNAC was negative in 32 and inadequate in 8. It showed no false-positive results. Thus, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of FNAC were 71%, 80%, 88%, 56%, and 74%, respectively. The ROC curve analysis demonstrated that the most appropriate cut-off value for the diagnosis of thyroid cancer metastatic lesions was 1.1 ng/mL (sensitivity 100%, specificity 100%, PPV 100%, NPV 100%, accuracy 100%; [Figure 1](#fig1){ref-type="fig"}, Tables [3](#tab3){ref-type="table"}, and [4](#tab4){ref-type="table"}). Basing on this cut-off level, the FNAC-Tg results correctly concluded all 25 malignant (100%) and 8 benign (100%) cases with false-negative (*n* = 4) and nondiagnostic (*n* = 29) FNAC results, respectively ([Table 5](#tab5){ref-type="table"}). The FNAC-Tg levels were significantly higher in malignant (median 513.8 ng/mL, range 1.7-\> 3000 ng/mL) than benign (median \<0.2 ng/mL, range \<0.2--1.1 ng/mL) lesions, respectively (*P* \< .0000001). Particularly, specimen Tg levels were undetectable (i.e., \<0.2 ng/mL) in 36 cases and were 0.3, 0.6, 0.8, and 1.1 ng/mL in remaining 4 cases with benign lesions.

4. Discussion {#sec4}
=============

An accurate discrimination between metastatic and reactive LNs is essential in the management of thyroid cancer. Cytological examination of FNAC samples disclosed by US has been the most accurate method to diagnose a cervical LN. However, as showed also in our study, its sensitivity is negatively impacted by the rate of nondiagnostic samples although FNAC procedures are performed by US-experienced physicians and dedicated cytopathologists \[[@B5], [@B6], [@B15]\]. In the present study 23% of samples were nondiagnostic; this perfectly conforms with previously reported data \[[@B18]\]. Cystic metastasis and partial LN involvement comprise most of the inadequate/nondiagnostic FNAC-cytology cases and could be misinterpreted as a benign cervical cystic mass or branchial cleft cysts and could therefore delay the correct diagnosis and a further radical neck lymphadenectomy. The immunocytochemical Tg staining on FNAC samples from of neck nodes was previously evaluated in patients with DTC. Because an adequate FNAC sample is required, however, the practical impact of this technique is limited in clinical practice \[[@B19]\]. Recently, the FNAC-Tg measurement has been proposed to be a useful diagnostic technique in the management of patients with thyroid cancer. Because Tg is produced only by follicular thyrocyte-derived cells, measurement of Tg in FNAC specimens of nonthyroidal tissues enables the detection of persistence, recurrence, or metastasis of differentiated thyroid carcinoma. In our study FNAC-Tg analysis was more sensitive for detecting metastasis when compared with FNAC alone, and allows the accurate diagnosis in samples with inconclusive cytology. Our results perfectly conforms those recently reported by Bournaud and colleagues \[[@B18]\]. By contrast Tg could be determined in all aspirates and a sensitivity of 100% was achieved in our series, that is at the higher end of previously reported data (81%--100%) \[[@B7], [@B9], [@B14], [@B17], [@B18]\]. Although the performance of FNAC-Tg is well established, the Tg threshold value remains controversial. The Tg assays employed and methods for determining the cut-off value differed from one study to another, resulting in a large range, from 0.9 ng/mL to values as high as 39 ng/mL, proposed in the literature.

In our study the best Tg threshold was determined at 1.1 ng/mL by ROC curve analysis. Using a threshold of 1.1 ng/mL we observe neither false-positive results in non-malignant LNs nor false-negative results in malignant LNs at final diagnosis. Additionally, FNAC-Tg results correctly classified as malignant 4 lesions that tested negatively in cytological examination. All in all, our results are in accordance with those of Snozek and colleagues that used a Tg assay with a functional sensitivity at 0.1 ng/mL and proposed a cut-off level of 1.00 ng/mL: basing on their results these authors suggested that FNAC-Tg should be substituted for FNAC in many cases \[[@B7]\]. Of  importance, our samples were obtained in a population of well-differentiated thyroid carcinomas (i.e., only two Hürtle cell and two tall-cell variants among 108 DTC cases). Several authors reported, however, that FNAC-Tg levels could be undetectable in some types of thyroid cancers (i.e., poorly differentiated thyroid carcinomas) \[[@B13], [@B17]\]. This correspond to the fact that amount and intensity of Tg expression parallel with differentiation of the tumor and could produce false-negative results. As a consequence, caution is needed, and a combination of FNAC and FNAC-Tg should remain the standard, especially in patients harboring less differentiated thyroid carcinomas.

5. Conclusions {#sec5}
==============

The diagnostic performance of needle washout FNAC-Tg measurement with a cut-off of 1.1 ng/mL compared favourably with cytology and allowed accurate diagnosis in all cases in whom cytology was nondiagnostic.
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![FNAC-Tg: ROC curve analysis.](JTR2011-621839.001){#fig1}

###### 

Patients characteristics and cytological, pathological, and biochemical data.

  Patients   Histology   pTNM      Duration (months)   Tg (ng/mL)   TgAb (IU/mL)   Lesions    Sites        FNA         Final diagnosis   
  ---------- ----------- --------- ------------------- ------------ -------------- --------- ------------- ----------- ----------------- ---------------
  1          PTC         pT1N1Mx   6                   1.0          \<60           1         R II          ND          \<0.2             B
  2          PTC         pT1NxMx   15                  4.6          \<60           1         L III         Negative    435.2             M
  3          PTC         pT1NxMx   18                  1.7          \<60           1         R IV          CTM         85.3              M
  4          PTC         pT1NxMx   30                  0.4          \<60           1         R III         ND          \<0.2             B
  5          PTC         pT1N0Mx   6                   3.1          \<60           1         L II          ND          97.2              M
  6          PTC         pT2N0Mx   19                  9.1          \<60           2         R IV, VI      CTM         118.5             M
  7          PTC         pT2NxMx   47                  \<0.2        334            1         L IV          CTM         879.4             M
  8          PTC         pT2N1Mx   6                   0.9          78             1         VI            Negative    1.1               B
  9          PTC         pT1N1Mx   9                   9.8          \<60           1         L II          ND          1348.6            M
  10         PTC         pT2N0Mx   14                  1.5          \<60           1         L III         CTM         358.5             M
  11         PTC         pT1NxMx   8                   12.6         \<60           3         R II          CTM         2387.4            M
  12         PTC         pT2NxMx   16                  9.7          \<60           1         R III         CTM         875.9             M
  13         PTC         pT1NxMx   9                   6.3          \<60           1         R II          CTM         958.6             M
  14         PTC         pT1N0Mx   11                  1.0          \<60           1         L III         Negative    48.7              M
  15         PTC         pT2N1Mx   39                  9.5          \<60           1         L IV          CTM         \>3000            M
  16         PTC         pT1NxMx   12                  0.8          \<60           1         L III         CTM         107.5             M
  17         PTC         pT2NxMx   19                  2.7          \<60           3         R III-IV      ND, CTM     541.6             RIII B, IV M
  18         PTC         pT4N1Mx   6                   1.6          \<60           1         L III         CTM         31.8              M
  19         PTC         pT1N1Mx   15                  0.5          289            1         R IV          ND          \<0.2             B
  20         PTC         pT2N1Mx   3                   2.3          \<60           1         L III         ND          540.7             M
  21         PTC         pT1NxMx   34                  4.1          \<60           1         L III         CTM         650.6             M
  22         PTC         pT2N1Mx   8                   \<0.2        98             1         L II          ND          5.8               M
  23         PTC         pT1NxMx   9                   0.8          \<60           2         R II, R III   CTM         87.5              M
  24         PTC         pT4N0Mx   10                  1.4          755            1         R II          CTM         196.4             M
  25         PTC         pT2NxMx   21                  11           \<60           1         R III         ND          585.3             M
  26         PTC         pT1NxMx   9                   \<0.2        \<60           1         R III         Negative    \<0.2             B
  27         PTC         pT4N1M    12                  1.1          160            1         L III         Negative    0.3               B
  28         PTC         pT1N0Mx   23                  5.3          \<60           1         R III         CTM         784.2             M
  29         PTC         pT2N1Mx   5                   \<0.2        \>1000         1         R III         ND          \<0.2             B
  30         PTC         pT2N0Mx   22                  4.9          \<60           1         R III         CTM         641.5             M
  31         PTC         pT1NxMx   36                  0.3          367            1         R IV          Negative    \<0.2             B
  32         PTC         pT1NxMx   15                  7.1          \<60           1         R III         ND          665.4             M
  33         PTC         pT2N0Mx   41                  \<0.2        \<60           1         L II          Negative    \<0.2             B
  34         PTC         pT1NxMx   24                  2.6          \<60           1         R III         CTM         570.6             M
  35         PTC         pT4N0Mx   31                  1.4          \>1000         3         L IV, VI      CTM         96.7              M
  36         PTC         pT4N1M    12                  27.1         \<60           1         R II          CTM         2987.3            M
  37         PTC         pT1N1Mx   54                  6.8          \<60           1         L III         CTM         875.6             M
  38         PTC         pT2NxMx   12                  \<0.2        149            1         R IV          Negative    \<0.2             B
  39         PTC         pT2N0Mx   9                   0.9          \<60           1         R II          Negative    \<0.2             B
  40         PTC         pT1N0Mx   34                  2.4          89             1         L III         ND          347.4             M
  41         PTC         pT2NxMx   14                  5.1          \<60           1         L IV          ND          1655.7            M
  42         PTC         pT4N1M    8                   7.7          \<60           1         L III         Negative    2076.5            M
  43         PTC         pT1NxMx   61                  1.1          \<60           1         VI            Negative    \<0.2             B
  44         PTC         pT2N0Mx   22                  1.0          \<60           1         L II          CTM         90.6              M
  45         PTC         pT2N1Mx   12                  6.4          \<60           2         R III-IV      CTM, ND     458.6             RIII M, IV B
  46         PTC         pT1NxMx   45                  0.6          \<60           1         R IV          Negative    \<0.2             B
  47         PTC         pT4N0Mx   36                  4.3          \<60           1         R III         CTM         766.4             M
  48         PTC         pT2NxMx   11                  1.9          \<60           1         L II          ND          306.5             M
  49         PTC         pT3NxMx   18                  7.0          \<60           1         R III         CTM         955.6             M
  50         PTC         pT2NxMx   10                  1.2          \<60           1         L III         Negative    \<0.2             B
  51         PTC         pT1N1Mx   12                  3.9          \<60           1         R III         CTM         564.7             M
  52         PTC         pT3N0Mx   25                  6.4          190            1         R III         ND          1078.6            M
  53         PTC         pT2N1Mx   16                  9.5          \<60           1         L IV          CTM         759.4             M
  54         PTC         pT1NxMx   9                   0.6          \<60           1         R III         Negative    \<0.2             B
  55         PTC         pT3N1Mx   60                  \<0.2        107            2         L II-III      CTM         137.5             M
  56         PTC         pT1N0Mx   11                  5.3          \<60           1         R II          CTM         654.8             M
  57         PTC         pT2N1Mx   18                  1.1          860            1         L III         ND          \<0.2             B
  58         PTC         pT1NxMx   9                   0.9          \<60           1         R IV          Negative    \<0.2             B
  59         PTC         pT2NxMx   28                  1.1          \<60           1         R III         ND          99.6              M
  60         PTC-TCV     pT3NxMx   13                  4.6          \<60           1         L II          CTM         436.8             M
  61         PTC         pT1NxMx   2                   2.7          \<60           1         R II          CTM         194.5             M
  62         PTC         pT3NxMx   7                   21.9         \<60           3         R III, L II   Neg., CTM   \>3000            RIII B, LII M
  63         PTC         pT1NxMx   18                  1.1          \<60           1         R III         CTM         27.4              M
  64         PTC         pT3NxMx   10                  3.5          \<60           1         VI            CTM         147.4             M
  65         PTC         pT2N0Mx   29                  \<0.2        \>1000         1         R IV          Negative    \<0.2             B
  66         PTC         pT3N1Mx   6                   5.6          \<60           1         L III         CTM         \<0.2             M
  67         PTC         pT1N1Mx   11                  2.1          \<60           1         R III         ND          \<0.2             M
  68         PTC         pT3N0Mx   18                  0.7          \<60           1         R III         ND          \<0.2             B
  69         PTC         pT2N0Mx   23                  1.7          \<60           1         L IV          CTM         75.6              M
  70         PTC         pT1NxMx   9                   3.5          \<60           1         L II          ND          72.6              M
  71         PTC         pT3N0Mx   18                  7.1          \<60           2         R IV, VI      CTM         386.2             RIV B, VI M
  72         PTC         pT1NxMx   7                   1.8                         1         L II          Negative    \<0.2             B
  73         PTC         pT2NxMx   11                  3.6          \<60           1         R III         ND          245.7             M
  74         PTC         pT2NxMx   29                  2.2          \<60           2         L III-IV      CTM         67.4              IV M, III B
  75         PTC         pT2N1Mx   14                  5.7          \<60           1         L II          CTM         198.7             M
  76         PTC         pT1N0Mx   8                   1.5          \<60           1         R IV          CTM         26.1              M
  77         PTC         pT2NxMx   10                  2.1          \<60           1         VI            CTM         59.7              M
  78         PTC         pT1NxMx   18                  0.7          \<60           1         R IV          Negative    \<0.2             B
  79         PTC         pT3N1Mx   34                  12.3         \<60           1         R III         ND          678.4             M
  80         PTC         pT1N1Mx   16                  1.8          \<60           1         L II          Negative    \<0.2             B
  81         PTC         pT2N0Mx   52                  0.9          \<60           1         R III         Negative    \<0.2             B
  82         PTC         pT2N1Mx   25                  9.4          \<60           1         L III         ND          563.6             M
  83         PTC         pT1NxMx   9                   4.1          \<60           1         VI            CTM         64.7              M
  84         PTC         pT2N1Mx   18                  3.1          \<60           1         R IV          CTM         116.4             M
  85         PTC-TCV     pT2NxMx   20                  15.5         \<60           3         R IV-L III    CTM         432.9             M
  86         PTC         pT3N0Mx   8                   \<0.2        56             1         VI            ND          \<0.2             B
  87         PTC         pT1N0Mx   31                  2.9          \<60           1         R IV          CTM         39.3              M
  88         PTC         pT2NxMx   11                  1.7          \<60           1         R III         Negative    \<0.2             B
  89         PTC         pT2NxMx   54                  6.5          \<60           1         L IV          ND          467.7             M
  90         PTC         pT1N1Mx   28                  0.3          651            1         R II          Negative    \<0.2             B
  91         PTC         pT2NxMx   12                  2.1          \<60           1         L III         CTM         88.6              M
  92         PTC         pT3N0Mx   17                  9.4          \<60           2         R IV, VI      CTM         156.2             IV M, VI B
  93         PTC         pT1NxMx   22                  1.0          \<60           1         L IV          Negative    \<0.2             B
  94         PTC         pT2N1Mx   9                   4.3          \<60           1         VI            Negative    53.8              M
  95         PTC         pT2N0Mx   26                  \<0.2        \<60           1         R IV          Negative    \<0.2             B
  96         PTC         pT1N0Mx   12                  0.9          \<60           1         R III         ND          2.7               M
  97         PTC         pT2NxMx   17                  8.1          \<60           1         L II          ND          356.4             M
  98         PTC         pT2NxMx   9                   0.9          \<60           1         R III         CTM         19.6              M
  99         PTC         pT3N1Mx   12                  1.1          \<60           1         L III         ND          0.6               B
  100        FTC         pT1N1Mx   45                  4.9          \<60           1         R III         CTM         117.5             M
  101        FTC         pT3N0Mx   36                  1.4          \<60           1         R III         Negative    \<0.2             B
  102        FTC         pT2N1Mx   11                  \<0.2        \>1000         2         R III-IV      Negative    \<0.2             B
  103        FTC (HC)    pT1NxMx   72                  10.4         \<60           1         R IV          ND          278.9             M
  104        FTC         pT2N1Mx   11                  0.7          \<60           1         R III         Negative    \<0.2             B
  105        FTC         pT1N0Mx   18                  2.1          \<60           1         R IV          CTM         74.4              M
  106        FTC (HC)    pT1N0Mx   6                   1.9          \<60           1         L III         Negative    0.8               B
  107        FTC         pT2N1Mx   25                  7.8          \<60           1         R II          ND          116.4             M
  108        FTC         pT1NxMx   19                  4.6          \<60           2         L II-III      CTM         89.5              M

FNA, fine-needle aspiration; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; TCV, tall-cell variant; HC Hürtle cell; R, right, L, left; duration, time from thyroid ablation to FNA; II-III-IV, upper, middle, lower neck lateral compartment, IV, central neck compartment.

###### 

Diagnostic performance of FNAC cytology as compared to final diagnosis.

               Final diagnosis   
  ------------ ----------------- ----
  Positive     61                0
  Negative     4                 32
  Inadequate   21                8

###### 

Diagnostic performance of FNAC-Tg as compared to final diagnosis.

                        Malignant LNs (*n* = 86)   Benign LNs (*n* = 40)
  --------------------- -------------------------- -----------------------
  FNAC-Tg \>1.1 ng/mL   86                         0
  FNAC-Tg ≤1.1 ng/mL    0                          40

###### 

Figures of merits of FNAC cytology and FNAC Tg.

  FNAC       Sensitivity   Specificity   PPV    NPV    Accuracy
  ---------- ------------- ------------- ------ ------ ----------
  Cytology   71%           80%           88%    56%    74%
  Tg         100%          100%          100%   100%   100%

###### 

Rate of positive FNAC-Tg values (i.e., \>1.1 ng/mL) in patients with inadequate or misdiagnosed FNAC-cytology.

  Final status               FNAC inadequate (*n* = 29)   FNAC false-negative (*n* = 4)
  -------------------------- ---------------------------- -------------------------------
  Malignant LNs (*n* = 25)   21/21                        4/4
  Benign LNs (*n* = 8)       0/8                          ---
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